S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)

Weight Watchers gains from Oprah’s GLP-1 weight-loss

GLENDALE, CA/USA - OCTOBER 24, 2015: Weight Watchers corporate office building. Weight Watchers is a company offering weight loss products and services.

Key Points

  • Media personality Oprah Winfrey revealed she has lost over 60 pounds using GLP-1 medication and WeightWatchers principles on Dec. 13, 2023.
  • This serves as a testimony and endorsement for WW through mainstream media as the company introduced its WeightWatchers GLP-1 treatment program the following day.
  • Guggenheim resumes its Buy rating on WW stock with a $14 price target, as shares trade with a 21.26% short interest.
  • 5 stocks we like better than WW International

Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication and WW International Inc. NYSE: WW (WeightWatchers) principles of nutrition and exercise. Winfrey has been a spokesperson, board member and shareholder since 2015. WW took advantage of the free publicity and announced the launch of its new Weight Watchers GLP-1 Program the following day.

This ringing endorsement helped propel shares over 10%. The clinical approach to weight management with GLP-1 treatments is a trend also embraced by telehealth platforms in the medical sector like Teladoc Health Inc. NYSE: TDOC, Hims & Hers Inc. NYSE: HIMS and LifeMD Inc. NASDAQ: LFMD.

GLP-1 tipping point

2023 was the tipping point for GLP-1 medication that spread like wildfire with the mainstream, similar to the artificial intelligence (AI) trend. It's no longer a secret among celebrities and influencers. Scientists and Oprah exclaim that obesity is a disease, and a clinical approach is proving to be an effective way to take the weight off.


Ozempic and Wegovy accounted for 52% of Novo Nordisk A/S NYSE: NVO revenues of $32.6 billion in the first nine months of 2023. Eli Lilly& Co. NYSE: LLY, maker of Mounjaro and Zepbound, has its shares risen 59.7%, driven by sales of its blockbuster GLP-1 drugs. While these two dominate the market for now, there are many more GLP-1 treatments in the works, like pemvidutide from Altimmune Inc. NASDAQ: ALT, which has shown to have more tolerable side effects than the incumbents.

Off-label usage spurs fast-track FDA approvals for obesity drugs.

GLP-1 drugs are once-a-week injections originally designed for type-2  diabetes patients to control blood sugar levels. However, they also produced an exceptional side effect, causing noticeable weight loss. Doctors prescribed drugs like Ozempic for off-label use to control obesity and weight loss, which prompted the FDA to fast-track approval of a weight-loss version of Ozempic called Wegovy.

They are the same medication, Semaglutide, but Wegovy is a more powerful version specifically tailored for obesity that helps suppress appetites and improve blood sugar levels, resulting in dramatic weight loss ranging from 15% to 20% of total body weight within a year. The downsides are the gastrointestinal side effects of nausea and vomiting and the costs typically over $1,000 a month if you don't have health insurance.   

Brilliant synergy from the Sequence acquisition

Sequence is a one-stop weight-management telehealth platform that has clinicians who can prescribe GLP-1 medications. WW acquired them in April 2023 to integrate them with its legacy subscription service. Sequence costs $99 a month for access to its program and prescriptions for GLP-1 drugs. The drug costs are not included, but they will work with patients and health insurers for claims and reimbursement solutions.

The addition of Sequence accessibility to its more than 3 million subscribers was a brilliant move and prompted a Strong Buy upgrade from Goldman Sachs with a $12 price target last year. Sequence has been completely integrated into WW and renamed WeightWatchers Clinic. Check out the sector heatmap on MarketBeat.

Shaping the turnaround

On Nov. 2, 2023, WW released its third-quarter fiscal 2023 results for the quarter ending September 2023. The company reported earnings-per-share (EPS) of 6 cents, matching consensus analyst estimates for 6 cents. Revenues fell 14% YoY to $214.87 million versus $221.62 million analyst estimates. Paid subscribers rose 6% to 4 million, driven by the growth of Digital Subscribers and the addition of 45,000 Clinical Subscribers, up 23% QoQ. Adjusted gross margins were 66.2%. The average monthly WeightWatchers plan is $23, and an additional $99 is charged for access to clinicians who can prescribe GLP-1 treatments.

Reaffirming guidance

The company issued fiscal full-year 2023 revenues of $890 million to $910 million versus $900.84 million consensus analyst estimates. Operating income is expected to be between $31 million and $43 million, down from $39 million to $51 million, from unexpected additional restructuring charges. Adjusted operating income, which excludes the restructuring charges, is expected to be within the previous guidance range of $80 million to $85 million.

CEO comments

WW International CEO Sima Sistani commented, “2023 has been a transformative year for WeightWatchers. We've returned our core business to subscriber growth, quickly positioned our Clinical business as the gold standard in weight health with the ability to scale as supply comes back and launched the next wave of enhancements to our product and program that will provide the foundation for a more engaging digital experience.”

WW International analyst ratings and price targets are at MarketBeat. WW International peers and competitor stocks can be found with the MarketBeat stock screener.

weight watchers stock chart

Daily cup pattern with a rounding bottom

The daily candlestick chart for WW illustrates a cup pattern that is completed after forming a rounding bottom. The pullbacks may bottom near the 200-period daily moving average to commence a handle from $8.22. The cup lip line commenced on Oct. 24, 2023, as WW fell to a multiple-bottom low near $6.31.

Shares formed a daily market structure low (MSL) trigger above $7.26. The rounding bottom eventually caused shares to steadily rise in December 2023 towards the lip line to complete the cup pattern on Dec. 22, 2023.

WW shares are in a pullback driven lower by the falling relative strength index (RSI) slipping under the 60-band. Pullback support levels are at $7.93, $7.26, $7.07 and $6.51.

→ Americans Now Favor Gold Over Stocks as an Investment Vehicle (From Edge On The Street) (Ad)

Should you invest $1,000 in WW International right now?

Before you consider WW International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WW International wasn't on the list.

While WW International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
WW International (WW)
2.3517 of 5 stars
$3.55+13.8%N/A-2.22Hold$10.36
Teladoc Health (TDOC)
2.9063 of 5 stars
$14.90-1.2%N/A-11.12Hold$23.44
Hims & Hers Health (HIMS)
3.0671 of 5 stars
$13.25+1.6%N/A-120.45Moderate Buy$13.45
Eli Lilly and Company (LLY)
4.8761 of 5 stars
$779.43+3.4%0.67%134.38Moderate Buy$663.33
Novo Nordisk A/S (NVO)
3.0857 of 5 stars
$122.46+2.2%0.51%45.27Moderate Buy$121.25
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

Search Headlines: